neuroscience

AbbVie Completes Acquisition of Cerevel Therapeutics

AbbVie has completed its acquisition of Cerevel Therapeutics. According to AbbVie, Cerevel's pipeline is highly complementary to its own existing neuroscience portfolio. The takeover was announced in December 2023.

News

AbbVie to Acquire Cerevel Therapeutics for $8.7 Billion

In a move to complement its neuroscience portfolio, US drugmaker AbbVie has agreed to acquire Cerevel Therapeutics, which has a pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson's disease (PD), and mood disorders.

News

AstraZeneca Tries New Tack in Brain Research

Top-Feature

Bio-Rad Laboratories

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Dow Chemical Company

Anchored in Sustainability

Together for Sustanability (TFS)

Driving Sustainability Through Collaboration

Brenntag SE

Brenntag Downsizes Management Board, Retains Both Divisions

Nova-Institut GmbH

Advanced Recycling Conference 2025: New Paths to the Circular Economy

Easyfairs Deutschland GmbH

Leading the way. Driving results.

Sasol

Leading Transformation

CHEManager International c/o Wiley-VCH GmbH

API Manufacturing

Concept Heidelberg

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

Special Issue

Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

AbbVie Inc.

Chemical Market Reporter